Change of Special Meeting Date

NZX/ASX Announcement
30 June 2025

TruScreen - Change of Special Meeting Date

Truscreen Group Limited (NZX/ASX:TRU) advises that the Special Meeting of Shareholders
scheduled for 11 July 2025 will now be held on 15 July 2025 at 11 am NZ Time.
The meeting will be held online only at:
www.virtualmeeting.co.nz/trusm25

This announcement has been approved by the Board.
Ends
Guy Robertson
Company Secretary
Tel: +61 407 983 270
Email: guyrobertson@truscreen.com

For more information, visit www.truscreen.com or contact:

Mr Martin Dillon
Chief Executive Officer
martindillon@truscreen.com



Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and
manufactures an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via
measurements of the low level of optical and electrical stimuli.
TruScreen’s cervical screening technology enables cervical screening, negating sampling and
processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly,
specialised personnel and supporting laboratory infrastructure.
The TruScreen device, TruScreen Ultra
®
, is typically registered as a primary screening device for cervical
cancer screening.
The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA
(Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS
(Mexico). It has Ministry of Health approval for use in Vietnam, Israel and the Philippines, among others
and has distributors in over 20 countries. In 2021, TruScreen established a manufacturing facility in
China for devices marketed and sold in China.
TruScreen technology has been recognised in CSCCP’s (Chinese Society for Colposcopy and Cervical
Pathology) China Cervical Cancer Screening Management Guideline.
TruScreen has been recognised in a China Blue Paper “Cervical Cancer Three Stage Standardized
Prevent and Treatment” published on 28 April 2023.
In Dec 2023 TruScreen technology was added to the Vietnam Ministry of Health approved National
Technical List, for use in Vietnam’s public and private healthcare sectors and in 2024 was added to the
Russian guidelines for the screening of cervical cancer.
In financial year 2025 alone, approximately 150,000
1
examinations were performed with the
TruScreen device. To date, over 200 devices have been installed and used in China, Vietnam, Mexico,
Zimbabwe, Russia, and Saudi Arabia. TruScreen’s vision is “A world without the cervical cancer”
©
.
To learn more, please visit: www.truscreen.com/.
1
Based on Single Use Sensor sales.